These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
240 related articles for article (PubMed ID: 35538553)
1. Intraocular pressure improvement in patients receiving teprotumumab for the treatment of thyroid eye disease: a case series. Chu M; Sung J; Song M; Song A; Song J J Med Case Rep; 2022 May; 16(1):195. PubMed ID: 35538553 [TBL] [Abstract][Full Text] [Related]
2. Teprotumumab for patients with active thyroid eye disease: a pooled data analysis, subgroup analyses, and off-treatment follow-up results from two randomised, double-masked, placebo-controlled, multicentre trials. Kahaly GJ; Douglas RS; Holt RJ; Sile S; Smith TJ Lancet Diabetes Endocrinol; 2021 Jun; 9(6):360-372. PubMed ID: 33865501 [TBL] [Abstract][Full Text] [Related]
3. Long-Term Efficacy of Teprotumumab in Thyroid Eye Disease: Follow-Up Outcomes in Three Clinical Trials. Kahaly GJ; Subramanian PS; Conrad E; Holt RJ; Smith TJ Thyroid; 2024 Jul; 34(7):880-889. PubMed ID: 38824618 [No Abstract] [Full Text] [Related]
4. Teprotumumab for the Treatment of Recalcitrant Thyroid Eye Disease. Men CJ; Amarikwa L; Pham B; Sears C; Clauss K; Lee BW; Lee WW; Pasol J; Ugradar S; Shinder R; Cockerham K; Wester S; Douglas R; Kossler AL Ophthalmic Plast Reconstr Surg; 2024 May-Jun 01; 40(3):276-285. PubMed ID: 37972960 [TBL] [Abstract][Full Text] [Related]
5. Teprotumumab for the Treatment of Active Thyroid Eye Disease. Douglas RS; Kahaly GJ; Patel A; Sile S; Thompson EHZ; Perdok R; Fleming JC; Fowler BT; Marcocci C; Marinò M; Antonelli A; Dailey R; Harris GJ; Eckstein A; Schiffman J; Tang R; Nelson C; Salvi M; Wester S; Sherman JW; Vescio T; Holt RJ; Smith TJ N Engl J Med; 2020 Jan; 382(4):341-352. PubMed ID: 31971679 [TBL] [Abstract][Full Text] [Related]
6. Teprotumumab and Orbital Decompression for the Management of Proptosis in Patients With Thyroid Eye Disease. Hubschman S; Sojitra B; Ghiam S; Sears C; Hwangbo N; Goldberg RA; Rootman DB Ophthalmic Plast Reconstr Surg; 2024 May-Jun 01; 40(3):270-275. PubMed ID: 37972968 [TBL] [Abstract][Full Text] [Related]
7. Successful Case of Teprotumumab Treatment in an Adolescent Patient With Thyroid Eye Disease. Radulovich N; Van Brummen A; Chambers C; Zhang M Ophthalmic Plast Reconstr Surg; 2024 Mar-Apr 01; 40(2):e65-e67. PubMed ID: 38231594 [TBL] [Abstract][Full Text] [Related]
8. Reactivation After Teprotumumab Treatment for Active Thyroid Eye Disease. Hwang CJ; Rebollo NP; Mechels KB; Perry JD Am J Ophthalmol; 2024 Jul; 263():152-159. PubMed ID: 38142982 [TBL] [Abstract][Full Text] [Related]
9. Objective Diplopia Outcomes for Patients Treated With Teprotumumab for Thyroid Eye Disease. Mudalegundi S; Huang P; Henderson AD; Carey AR J Neuroophthalmol; 2024 Mar; 44(1):80-86. PubMed ID: 38294416 [TBL] [Abstract][Full Text] [Related]
10. Real-World Experience With Teprotumumab in Patients With Dysthyroid Optic Neuropathy. Tamhankar MA; Pradeep T; Chen Y; Briceño CA J Neuroophthalmol; 2024 Mar; 44(1):74-79. PubMed ID: 37751310 [TBL] [Abstract][Full Text] [Related]
11. Teprotumumab Efficacy, Safety, and Durability in Longer-Duration Thyroid Eye Disease and Re-treatment: OPTIC-X Study. Douglas RS; Kahaly GJ; Ugradar S; Elflein H; Ponto KA; Fowler BT; Dailey R; Harris GJ; Schiffman J; Tang R; Wester S; Jain AP; Marcocci C; Marinò M; Antonelli A; Eckstein A; Führer-Sakel D; Salvi M; Sile S; Francis-Sedlak M; Holt RJ; Smith TJ Ophthalmology; 2022 Apr; 129(4):438-449. PubMed ID: 34688699 [TBL] [Abstract][Full Text] [Related]
12. Efficacy and Safety of Teprotumumab in Patients With Thyroid Eye Disease of Long Duration and Low Disease Activity. Douglas RS; Couch S; Wester ST; Fowler BT; Liu CY; Subramanian PS; Tang R; Nguyen QT; Maamari RN; Ugradar S; Hsu K; Karon M; Stan MN J Clin Endocrinol Metab; 2023 Dec; 109(1):25-35. PubMed ID: 37925673 [TBL] [Abstract][Full Text] [Related]
13. Acquired Epiblepharon Alleviated With Teprotumumab Treatment in Active Thyroid Eye Disease Patient. Chen KW; Phelps PO Ophthalmic Plast Reconstr Surg; 2021 Nov-Dec 01; 37(6):e195-e196. PubMed ID: 34269764 [TBL] [Abstract][Full Text] [Related]
15. Proptosis and Diplopia Response With Teprotumumab and Placebo vs the Recommended Treatment Regimen With Intravenous Methylprednisolone in Moderate to Severe Thyroid Eye Disease: A Meta-analysis and Matching-Adjusted Indirect Comparison. Douglas RS; Dailey R; Subramanian PS; Barbesino G; Ugradar S; Batten R; Qadeer RA; Cameron C JAMA Ophthalmol; 2022 Apr; 140(4):328-335. PubMed ID: 35175308 [TBL] [Abstract][Full Text] [Related]
16. A comparison of proptosis reduction with teprotumumab versus surgical decompression based on fat-to-muscle ratio in thyroid eye disease. Ting MAJ; Topilow NJ; Ediriwickrema LS; Yoon JS; Liu CY; Korn BS; Kikkawa DO Orbit; 2024 Apr; 43(2):222-230. PubMed ID: 37978819 [TBL] [Abstract][Full Text] [Related]
17. Teprotumumab for thyroid eye disease: early response is not required for benefit. Ugradar S; Wang Y; Mester T; Kahaly GJ; Douglas RS Eye (Lond); 2022 Jul; 36(7):1403-1408. PubMed ID: 34183792 [TBL] [Abstract][Full Text] [Related]
18. Improvement of asymmetric thyroid eye disease with teprotumumab. Ugradar S; Wang Y; Mester T; Kahaly GJ; Douglas R Br J Ophthalmol; 2022 Jun; 106(6):755-759. PubMed ID: 33579690 [TBL] [Abstract][Full Text] [Related]